All patients
non invasive oxygen
anti-inflammatory therapies in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
0.43 [0.04 ; 4.86 ] Shi, 2020, Shu, 2020 2 0% 141 moderate not evaluable deathsdetailed results COLCHIVID, 2021 0.69 [0.20; 2.40]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
0.62 [0.21 ; 1.90 ] COLCHIVID, 2021, Shi, 2020, Shu, 2020 3 0% 267 NA not evaluable clinical deteriorationdetailed results Shu, 2020 0.27 [0.01; 5.58]
0.27 [0.01 ; 5.58 ] Shu, 2020 1 0% 41 NA not evaluable clinical improvementdetailed results Shu, 2020 10.27 [1.17; 90.18]
10.27 [1.17 ; 90.18 ] Shu, 2020 1 0% 41 NA not evaluable clinical improvement (14-day)detailed results Shu, 2020 10.27 [1.17; 90.18]
10.27 [1.17 ; 90.18 ] Shu, 2020 1 0% 41 NA not evaluable clinical improvement (28-day)detailed results Shu, 2020 3.68 [0.18; 75.54]
3.68 [0.18 ; 75.54 ] Shu, 2020 1 0% 41 NA not evaluable clinical improvement (7-day)detailed results Shu, 2020 6.72 [1.50; 30.07]
6.72 [1.50 ; 30.07 ] Shu, 2020 1 0% 41 NA not evaluable hospital dischargedetailed results COLCHIVID, 2021 1.13 [0.76; 1.67]
1.13 [0.76 ; 1.67 ] COLCHIVID, 2021 1 0% 126 NA not evaluable mechanical ventilationdetailed results Shu, 2020 0.59 [0.02; 14.04]
0.59 [0.02 ; 14.04 ] Shu, 2020 1 0% 41 NA not evaluable serious adverse eventsdetailed results Shi, 2020 1.08 [0.04; 32.96]
1.08 [0.04 ; 32.96 ] Shi, 2020 1 0% 100 NA not evaluable adverse eventsdetailed results Shi, 2020 0.88 [0.38; 2.03]
Shu, 2020 2.48 [0.05; 132.54]
0.92 [0.41 ; 2.09 ] Shi, 2020, Shu, 2020 2 0% 141 moderate not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-03-29 15:25 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615
- roots T: 290